Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Although it is a rare disease, the number of available therapeutic options for treating
pulmonary arterial hypertension has increased since the late 1990s, with multiple drugs …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

The clinical classification of pulmonary hypertension (PH) has guided diagnosis and
treatment of patients with PH for several decades. Discoveries relating to underlying …

Abstract Background and Aims Interventional studies in pulmonary arterial hypertension
completed to date have shown to be effective in symptomatic patients with significantly …

Pulmonary arterial hypertension (PAH) is a deadly disease, characterized by increased
vascular resistance, pulmonary arteriolar loss, and occlusive arterial remodeling, leading to …

Rationale: To date, it remains unclear whether recent changes in the management of
patients with systemic sclerosis–associated pulmonary hypertension (SSc-PH) have …

Aims According to current guidelines, initial monotherapy should be considered for
pulmonary arterial hypertension (PAH) patients with cardiopulmonary comorbidities. This …